Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 14/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3277958 | 0.93 | MAPT (0.47) | GSK3BPDE10A | |
| SCHEMBL3280340 | 0.91 | GSK3B (0.42) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL3273968 | 0.89 | GSK3B (0.52) | GSK3BPDE10ACYP1A2CYP2D6 | |
| SCHEMBL3273287 | 0.88 | POLB (0.52) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL3274005 | 0.87 | HTR4 (0.45) | CYP1A2CYP2D6 | |
| SCHEMBL3277980 | 0.87 | NPC1 (0.42) | GSK3BPDE10ACYP1A2CYP2D6 | |
| SCHEMBL3273623 | 0.85 | GSK3B (0.45) | GSK3BPDE10ACYP1A2CYP2D6 | |
| SCHEMBL3277950 | 0.84 | GSK3B (0.46) | GSK3BPDE10ACYP1A2CYP2D6 | |
| SCHEMBL3274983 | 0.84 | ALDH1A1 (0.43) | GSK3BPDE10ACYP1A2CYP2D6 | |
| SCHEMBL3277436 | 0.83 | GSK3B (0.48) | GSK3BCYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8592436-B2 | Arylamide pyrimidone derivatives | SANOFI (FR) | 2013-11-26 | — | — | US | claimed |
| EP-2148866-B1 | ARYLAMIDE PYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SANOFI SA (FR) | 2013-07-17 | — | — | EP | claimed |
| US-20100087460-A1 | ARYLAMIDE PYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2010-04-08 | — | — | US | claimed |
| EP-2148866-A2 | ARYLAMIDE PYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Sanofi-Aventis (FR) | 2010-02-03 | — | — | EP | claimed |
| WO-2008155669-A2 | ARYLAMIDE PYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SANOFI-AVENTIS (FR) | 2008-12-24 | — | — | WO | claimed |
| EP-1992620-A1 | Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases | Sanofi-Aventis (FR) | 2008-11-19 | — | — | EP | claimed |
| US-8592436-B2 | Arylamide pyrimidone derivatives | SANOFI (FR) | 2013-11-26 | — | — | US | disclosed |
| US-20100087460-A1 | ARYLAMIDE PYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2010-04-08 | — | — | US | disclosed |
| EP-2148866-A2 | ARYLAMIDE PYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Sanofi-Aventis (FR) | 2010-02-03 | — | — | EP | disclosed |
| WO-2008155669-A2 | ARYLAMIDE PYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SANOFI-AVENTIS (FR) | 2008-12-24 | — | — | WO | disclosed |
| EP-1992620-A1 | Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases | Sanofi-Aventis (FR) | 2008-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087460-A1 | ARYLAMIDE PYRIMIDONE DERIVATIVES | DHFR, XDH, HPRT1 | GSK3B 3247/4885PDE10A 1271/4885CYP1A2 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.